Research is an important part of our pursuit of better health. Through research, we gain a better understanding of food allergies, how to manage them, potential treatments, ways to improve quality of life, and hopefully a cure.
We work with physicians, researchers, patients, caregivers, public health, and government agencies to conduct and support research that is important to people affected by food allergies and other allergic conditions.
As a person with food allergies or a caregiver, you can get involved in research in different ways and have a major impact on food allergy research. Here are some of the ways you can help improve treatments, education, and awareness right now:
Surveys
Share Your Thoughts on Quick-Relief Inhalers
If you or a loved one have asthma and use a quick-relief (or rescue) inhaler, take this survey about your experiences. The results will help make sure new products line up with your needs and preferences.
You must be 18 years or older and live in the United States to take the survey. At the end of the survey, you can enter for a chance to get one of five $100 gift cards.
Sponsored by Vitapul
Interviews and Focus Groups
Food Allergy Interview Participants Needed
My name is Rebeca, and I work at Global Patients, an IQVIA business. We are currently conducting a research study on food allergies and would like to invite adolescents and caregivers of children to participate.
This research study consists of a web-assisted interview in the U.S., which will last around 60 minutes and for which you will receive an honorarium of USD135 (USD100 for completing the interview, and USD35 for providing a confirmation of diagnosis) via virtual card.
There is no medical treatment being provided as part of this study. The research is completely anonymous, and no questions will be asked which could allow us to identify you as a participant. All data collected during this research will be treated anonymously, confidentially, and reported in aggregate form.
In order to confirm that you are eligible for this study, I will need to ask you a few preliminary questions on a quick phone call.
We hope you will find the time to share your views and experiences for this research study.
If you are interested, please contact rebeca@global-patients.com
Sponsored by Global Patients
Latest News on Food Allergies, Asthma, and Other Allergic Conditions
- New CDC Data on Allergic Conditions
The Centers for Disease Control and Prevention (CDC) recently released two data briefs on diagnosed allergic conditions in adults and children. Data briefs are topic-specific documents focusing on public health issues. The data briefs show that in 2021, nearly 1 in 3 adults and more than 1 in 4 children in the U.S. had seasonal allergies, eczema, or food allergies. Almost 6% of U.S. adults and children have a food allergy.
These data briefs also look at the differences in allergy trends between sex, age, race, and Hispanic ethnicity, showing that non-Hispanic Black adults and children are more likely to have food allergy than non-Hispanic white or Hispanic adults and children.
- FDA Lifts Partial Clinical Hold on Viaskin Peanut Patch for the Treatment of Peanut Allergy
A “partial clinical hold” is a delay or a suspension of part of a clinical study. Viaskin Peanut is a new type of treatment (a skin patch) being studied for peanut allergy treatment. The goal of the Phase 3 trial, called VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy), is to study the modified Viaskin Peanut patch in children ages 4 to 7 years old with peanut allergy. If approved by the Food and Drug Administration (FDA), the Viaskin Peanut patch will be the first treatment of its kind available for children with peanut allergy. - FDA Approves ODACTRA® Tablet for Sublingual Use as Immunotherapy for Adolescents
ODACTRA® is a tablet that can help treat allergy symptoms to house dust mites. It is a type of treatment called sublingual immunotherapy (SLIT), where a tablet is placed under the tongue and then swallowed when dissolved. The tablets will increase your tolerance to certain allergens and reduce your symptoms over time. ODACTRA® was first approved by the FDA in 2017 for people ages 18 to 65. It is now approved for people ages 12 to 65.
- Clinical Guidance for the Use of Dupilumab (Dupixent) in EoE Published in the Annals of Allergy, Asthma, and Immunology
The American College of Allergy, Asthma, and Immunology (ACAAI) published two new yardsticks to help doctors better understand the range of treatments available for allergic conditions. In May 2022, the FDA approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in patients 12 and older. It is the first and only FDA-approved treatment for EoE. This new yardstick provides guidance for how doctors can use dupilumab in treating patients with EoE.
Coming Soon!
Keep an eye out for the Asthma and Allergy Foundation of America’s (AAFA) upcoming 2023 Allergy Capitals™ report in March. (KFA is the food allergy division of AAFA.)
It is important to stay up to date on news about food allergies. By joining our community and following our blog, you will receive news about research and treatments. Our community also provides an opportunity to connect with other people who manage food allergies for support.
Comments (0)